Long-term finasteride doesn't impair quality of life

September 13, 2012
Long-term finasteride doesn't impair quality of life
Taking finasteride to prevent prostate cancer does not negatively affect the physical function, mental health, or vitality domains of health-related quality of life, according to a study published online Sept. 12 in the Journal of the National Cancer Institute.

(HealthDay)—Taking finasteride to prevent prostate cancer does not negatively affect the physical function, mental health, or vitality domains of health-related quality of life, according to a study published online Sept. 12 in the Journal of the National Cancer Institute.

Carol M. Moinpour, Ph.D., from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues examined the effect of finasteride on quality of life using data from questionnaires completed by Trial participants, who were randomized to finasteride or placebo for prevention of prostate cancer. Questionnaires were completed at enrollment (three months before randomization), six months after randomization, and annually for seven years. Three health-related quality-of-life domains were measured using the Health Survey Short Form 36: Physical Functioning, Mental Health, and Vitality scales.

The researchers found that finasteride had minor effects on physical function, accounting for less than a one-point difference over time in physical functioning scores. There were significant negative effects on physical function for comorbidities (including , leg pain, and diabetes), current smoking, and time on study. There were no significant effects of finasteride on mental health and vitality at any of the three time points, either in the mixed-effects analyses or in the cross-sectional analysis.

"In conclusion, taking finasteride for seven years did not appear to harm general aspects of health-related quality of life," the authors write.

Merck Inc. provided the drug and placebo used in the study.

Explore further: Hair loss drug shows long-term sexual side effects

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Hair loss drug shows long-term sexual side effects

July 23, 2012
(HealthDay) -- For men with finasteride-associated side effects, sexual dysfunction may persist for months or years, even after discontinuation of the drug, according to a study published online July 12 in The Journal of ...

Recommended for you

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.